Life Science Investing Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
Life Science Investing Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Life Science Investing Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Life Science Investing Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
Life Science Investing Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
